About

We are investigating antisense RNA compounds to treat
diseases with unmet medical needs

The potential for anti-microRNAs in the treatment of Myotonic Dystrophy

Our main objective is to find and develop treatments to address unmet medical needs. The first target of the company is the investigation of a treatment of myotonic dystrophy Type 1 (DM1), which is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000). Our preclinical research has revealed a new therapeutic target for investigation.

“Investigating antisense RNAs treatments for unmet medical needs”
Our crew

Meet our passionate team

Our Board of Advisors

Our Investors